Hemophilia A and B Recombinant Factor Replacement Therapy - Current and Future Players

Home/Hemophilia A and B Recombinant Factor Replacement Therapy - Current and Future Players

Hemophilia A and B Recombinant Factor Replacement Therapy - Current and Future Players

Regulation & Policy (Pharma & Healthcare), Finance & Investment (Pharma & Healthcare), Deals & Alliances (Pharma & Healthcare), Pharma & Healthcare

Publication ID:

GDA1215630

Publication Date:

December 11, 2015

Pages:

Publisher:

GlobalData

Region:

Global

$2,995.00

Need Custom Market Research Solution?

Want to commission a custom market research to suit your needs? We are here to help. Let us know.

Printer version

Send by email

PDF version

Tabs

Description

Hemophilia A and B Recombinant Factor Replacement Therapy - Current and Future Players

Summary

GlobalData has released its pharma report, “Hemophilia A and B Recombinant Factor Replacement Therapy - Current and Future Players”. The report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing Hemophilia A and B Market. The report identifies and analyses the key companies shaping and driving the global Hemophilia A and B market. The report provides insight into the competitive Hemophilia A and B landscape, including new companies entering the market. This report is built using data and information sourced from proprietary databases, primary and secondary and in-house analysis by GlobalData’s team of industry experts.

*This is an on-demand report and will be delivered within 24 hrs. (excluding weekends) of the purchase.

Scope

- Investigation of current and future market competition for Hemophilia A and B
- Competitor assessment
- Coverage of key market players and company profiles including business description, financial overview and SWOT analysis.
- Strategic assessment of Hemophilia A and B sector through market impact analysis, future market scenario and company analysis

Reasons to buy

- Gain a high level view of the trends shaping and driving Hemophilia A and B market
- Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition.
- Create an effective counter-strategy to gain a competitive advantage against those currently in the market
- What’s the next big thing in the global Hemophilia A and B market landscape? Identify, understand and capitalize

Table of Contents

1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Catalyst
2.2 Related Reports
2.3 Upcoming Related Reports
3 Market Outlook
3.1 Global Markets
3.1.1 Forecast
3.1.2 Drivers and Barriers - Global Market
4 Current and Future Players
4.1 Overview
4.2 Trends in Corporate Strategy
4.3 Company Profiles
4.3.1 Baxalta
4.3.2 Bayer
4.3.3 Biogen
4.3.4 CSL Behring
4.3.5 Novo Nordisk
4.3.6 Pfizer
5 Appendix
5.1 Bibliography
5.2 Abbreviations
5.3 Methodology
5.4 Forecasting Methodology
5.4.1 Diagnosed Hemophilia Patients
5.4.2 Percent Drug-Treated Patients
5.4.3 Drugs Included in Each Therapeutic Class
5.4.4 Launch Dates
5.4.5 General Pricing Assumptions
5.4.6 Individual Drug Assumptions
5.4.7 Pricing of Pipeline Agents
5.5 Primary Research - KOLs Interviewed for this Report
5.6 Primary Research - Prescriber Survey
5.7 Real-World Data
5.8 About the Authors
5.8.1 Analyst
5.8.2 Therapy Area Director
5.8.3 Epidemiologists
5.8.4 Global Head of Healthcare
5.9 About GlobalData
5.10 Disclaimer

1.1 List of Tables
Table 1: Sales Forecast ($m) for Hemophilia A and B Recombinant Therapies in the 7MM+A, 2014-2024
Table 2: Global Hemophilia A and B Market - Drivers and Barriers, 2014-2024
Table 3: Key Companies in the Hemophilia A and B Recombinant Therapies Market, 2014-2024
Table 4: Baxalta’s Hemophilia Recombinant Portfolio Assessment, 2015
Table 5: Baxalta SWOT Analysis, 2015
Table 6: Bayer’s Hemophilia Recombinant Portfolio Assessment, 2015
Table 7: Bayer SWOT Analysis, 2015
Table 8: Biogen’s Hemophilia Recombinant Portfolio Assessment, 2015
Table 9: Biogen SWOT Analysis, 2015
Table 10: CSL Behring’s Hemophilia Recombinant Portfolio Assessment, 2015
Table 11: CSL Behring SWOT Analysis, 2015
Table 12: Novo Nordisk’s Hemophilia Recombinant Portfolio Assessment, 2015
Table 13: Novo Nordisk SWOT Analysis, 2015
Table 14: Pfizer’s Hemophilia Recombinant Portfolio Assessment, 2015
Table 15: Pfizer SWOT Analysis, 2015
Table 16: Key Launch Dates
Table 17: Physicians Surveyed

1.2 List of Figures
Figure 1: Global Sales for Hemophilia A and B Recombinant Therapies by Region, 2014-2024
Figure 2: Company Portfolio Analysis in Hemophilia A and B, 2014-2024

Companies Covered

Baxalta
Bayer
Biogen
CSL Behring
Novo Nordisk
Pfizer

Report License Types

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

Report Enquiry

Do you need more information about this report before making a purchase decision or wish to customize this report to suite your requirements?

If yes, then please use the form given below and we will get in touch with you immediately.

Kindly use your official email address and contact number to ensure speedy response.

Name *

Email *

Company

Contact Number *

Report Title *

Your Message

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Drag or click the correct shape to the grey "drop area".